A porphyrin-based metallacage for enhanced photodynamic therapy

Jiao, Jingjing; He, Jiang; Li, Mengmeng; Yang, Jingxia; Yang, Hong; Wang, Xiao-Qing; Yang, Shiping

doi:10.1039/d1nr08293k

Cited by 27 publications

(14 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recently independent studies from our group [ 68 , 69 ] and the group of Janet R Morrow [ 70 ] demonstrated that water soluble metal–organic cages (MOC) with multiple Fe(III) centers are promising alternatives to prepare multinuclear Fe(III) complexes [ 71 ]. In our study, two water soluble metal-organic cages with two (MOC-Fe(III) 2 ) and four Fe(III) centers (MOC–Fe(III) 4 ) based on the bisbidentate catecholate ligand were prepared ( Figure 11 ) [ 68 ].…”

Section: Multinuclear Fe(iii) Complexesmentioning

confidence: 99%

Low-Molecular-Weight Fe(III) Complexes for MRI Contrast Agents

Chen

Yang

2022

Molecules

Self Cite

View full text Add to dashboard Cite

Fe(III) complexes have again attracted much attention for application as MRI contrast agents in recent years due to their high thermodynamic stability, low long-term toxicity, and large relaxivity at a higher magnetic field. This mini-review covers the recent progress on low-molecular-weight Fe(III) complexes, which have been considered as one of the promising alternatives to clinically used Gd(III)-based contrast agents. Two kinds of complexes including mononuclear Fe(III) complexes and multinuclear Fe(III) complexes are summarized in sequence, with a specific highlight of the structural relationships between the complexes and their relaxivity and thermodynamic stability. In additional, the future perspectives for the design of low-molecular-weight Fe(III) complexes for MRI contrast agents are suggested.

show abstract

Section: Multinuclear Fe(iii) Complexesmentioning

confidence: 99%

Low-Molecular-Weight Fe(III) Complexes for MRI Contrast Agents

Chen

Yang

2022

Molecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Current evidence suggests that tortuous and highly permeable tumor vessels cause accumulation of vascular macromolecules in tumor tissues and high interstitial fluid pressure (IFP), which prevents drug penetration ( 104 ). Furthermore, high IFP can aggravate the abnormal vascular network and hypoxia environment ( 105 ). Sirin Yonucu et al.…”

Section: Nanomaterials With Tumor Vascular-targeting Properties Promo...mentioning

confidence: 99%

“…The results indicated that PM@HAase-mPEG treatment could increase the density of blood vessels, blood perfusion and oxygen content. In addition, normalizing tumor vasculature via HAase could enhance the efficacy of PDT therapy for breast cancer ( 105 ).…”

Section: Nanomaterials With Tumor Vascular-targeting Properties Promo...mentioning

confidence: 99%

Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy

et al. 2022

View full text Add to dashboard Cite

Anti-angiogenesis therapy and immunotherapy are the first-line therapeutic strategies for various tumor treatments in the clinic, bringing significant advantages for tumor patients. Recent studies have shown that anti-angiogenic therapy can potentiate immunotherapy, with many clinical trials conducted based on the combination of anti-angiogenic agents and immune checkpoint inhibitors (ICIs). However, currently available clinical dosing strategies and tools are limited, emphasizing the need for more improvements. Although significant progress has been achieved, several big questions remained, such as how to achieve cell-specific targeting in the tumor microenvironment? How to improve drug delivery efficiency in tumors? Can nanotechnology be used to potentiate existing clinical drugs and achieve synergistic sensitization effects? Over the recent few years, nanomedicines have shown unique advantages in antitumor research, including cell-specific targeting, improved delivery potentiation, and photothermal effects. Given that the applications of nanomaterials in tumor immunotherapy have been widely reported, this review provides a comprehensive overview of research advances on nanomaterials in anti-angiogenesis therapy, mainly focusing on the immunosuppressive effects of abnormal tumor vessels in the tumor immune microenvironment, the targets and strategies of anti-angiogenesis nanomedicines, and the potential synergistic effects and molecular mechanisms of anti-angiogenic nanomedicines in combination with immunotherapy, ultimately providing new perspectives on the nanomedicine-based synergy between anti-angiogenic and immunotherapy.

show abstract

“…[1][2][3][4] Among existing treatment methods, photodynamic therapy (PDT) has been focused on specific tumors due to its minimal trauma and precise selectivity. [5][6][7] More importantly, PDT has potential for synergistic treatment with other therapies. [8][9][10][11] During the PDT process, photosensitizers (PSs), which can generate reactive oxygen species (ROS), are key factors for efficiently ablating cancer cells under laser irradiation and have received widespread attention from materials scientists in recent years.…”

Section: Introductionmentioning

confidence: 99%